Table 1

Baseline characteristics of included studies

Author (Year)

N

Mean age

% Male Participants

Mean disease severity score

Type of treatment

Outcomes

FU time(month)

QA score


Intervention (dosage)

Control


Adour et al. (1996) [8]

99

43

50

3 (FPRP)

Acyclovir 2,000 mg/day × 10 days Prednisolone 30 mg/kg/day × 5 days, 10 mg/day × next 5 days

Prednisolone with the same dosage

FPRI ≥ 8

4

7

De Diego et al. (1998)[25]

101

-

-

-

Acyclovir 2,400 mg/day ×10 days

Prednisolone 1 mg/kg/day × 10 days, taper over next 6 days

HB grade ≤ II, FPRI score≥ 8

3

3

Hato et al. (2007)[10]

221

50

53

15 (Yanagihara)

Valacyclovir 1,000 mg/day × 5 days Prednisolone 60 mg/day for 5 days, taper with Mecobalamin 1·5 mg/day × 6 months

Placebo

Yanagihara score > 36 points, no facial contracture or synkinesis

6

9

Sullivan et al. (2007) [12]

551

44

51

3.6 (HB)

Acyclovir 2000 mg/day × 10 days Prednisolone 50 mg/day × 10 days

Placebo

HB grade I

3, 9

12

Yeo et al. (2008)[13]

91

41

45

3.7 (HB)

Acyclovir 2,400 mg/day × 5 days Prednisolone 1 mg/kg/day × 4 days with maximum of 80 mg/day, 60 mg/day × 5-6 day, 40 mg/day × 7-8 day, 20 mg/day × 9-10 day

Placebo

HB grade ≤ II

2, 6

2

Engstrom et al. (2008) [9]

829

40

59

4 by HB

Valacyclovir 3,000 mg/day × 7 days Prednisolone 60 mg/day × 5 days, 10 mg/day until 10 days

Placebo

Sunnybrook 100/100, HB ≤ II

1, 2, 3, 6, 12

12


Numthavaj et al. BMC Neurology 2011 11:1   doi:10.1186/1471-2377-11-1

Open Data